Incannex Healthcare Inc
IXHL0.443USD
+0.005+1.10%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
153.93MMarket Cap
LossP/E TTM
More Details of Incannex Healthcare Inc Company
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Incannex Healthcare Inc Info
Ticker SymbolIXHL
Company nameIncannex Healthcare Inc
IPO dateMar 18, 2022
CEOLatham (Joel)
Number of employees12
Security typeOrdinary Share
Fiscal year-endMar 18
Address8 Century Circuit
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code2153
Phone61409840786
Website
Ticker SymbolIXHL
IPO dateMar 18, 2022
CEOLatham (Joel)
Company Executives of Incannex Healthcare Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
24.19M
+1433.21%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
2.57M
+14257.55%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
2.46M
+219.16%
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
1.96M
+622.84%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
24.19M
+1433.21%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
2.57M
+14257.55%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
2.46M
+219.16%
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
1.96M
+622.84%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Australia
74.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Latham (Joel)
6.99%
Valentine (Troy Robert)
3.56%
Swan (Joseph)
0.74%
Anastassov (George)
0.71%
Widdows (Peter)
0.57%
Other
87.43%
Shareholders
Shareholders
Proportion
Latham (Joel)
6.99%
Valentine (Troy Robert)
3.56%
Swan (Joseph)
0.74%
Anastassov (George)
0.71%
Widdows (Peter)
0.57%
Other
87.43%
Shareholder Types
Shareholders
Proportion
Individual Investor
12.79%
Investment Advisor
0.74%
Research Firm
0.25%
Investment Advisor/Hedge Fund
0.03%
Hedge Fund
0.03%
Venture Capital
0.02%
Other
86.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
39
3.21M
0.92%
+1.81M
2025Q2
39
10.29M
34.95%
+3.27M
2025Q1
36
6.86M
34.69%
+1.54M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Latham (Joel)
1.24M
0.36%
-335.00K
-21.24%
Apr 09, 2025
Valentine (Troy Robert)
869.01K
0.25%
-167.50K
-16.16%
Apr 09, 2025
Swan (Joseph)
17.93K
0.01%
-151.27K
-89.40%
Apr 09, 2025
Anastassov (George)
744.72K
0.21%
-25.00K
-3.25%
Apr 09, 2025
Widdows (Peter)
245.85K
0.07%
-25.00K
-9.23%
Apr 09, 2025
Changoer (Lekhram)
639.55K
0.18%
--
--
Apr 09, 2025
AdvisorShares Investments, LLC
343.95K
0.1%
+48.92K
+16.58%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
1.15%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
Proportion1.15%
Amplify Alternative Harvest ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Incannex Healthcare Inc?
The top five shareholders of Incannex Healthcare Inc are:
Latham (Joel) holds 1.24M shares, accounting for 0.36% of the total shares.
Valentine (Troy Robert) holds 869.01K shares, accounting for 0.25% of the total shares.
Swan (Joseph) holds 17.93K shares, accounting for 0.01% of the total shares.
Anastassov (George) holds 744.72K shares, accounting for 0.21% of the total shares.
Widdows (Peter) holds 245.85K shares, accounting for 0.07% of the total shares.
Latham (Joel) holds 1.24M shares, accounting for 0.36% of the total shares.
Valentine (Troy Robert) holds 869.01K shares, accounting for 0.25% of the total shares.
Swan (Joseph) holds 17.93K shares, accounting for 0.01% of the total shares.
Anastassov (George) holds 744.72K shares, accounting for 0.21% of the total shares.
Widdows (Peter) holds 245.85K shares, accounting for 0.07% of the total shares.
What are the top three shareholder types of Incannex Healthcare Inc?
The top three shareholder types of Incannex Healthcare Inc are:
Latham (Joel)
Valentine (Troy Robert)
Swan (Joseph)
Latham (Joel)
Valentine (Troy Robert)
Swan (Joseph)
How many institutions hold shares of Incannex Healthcare Inc (IXHL)?
As of 2025Q3, 39 institutions hold shares of Incannex Healthcare Inc, with a combined market value of approximately 3.21M, accounting for 0.92% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -34.02%.
What is the biggest source of revenue for Incannex Healthcare Inc?
In FY2025Q1, the -- business generated the highest revenue for Incannex Healthcare Inc, amounting to -- and accounting for --% of total revenue.
